Worth reading
54Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-443
¥ million (year-on-year change in net sales)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportSecond quarter (interim period) of the fiscal year ending December 20269 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥3,533 million-11.1%
Operating profit¥996 million-32.5%
Ordinary income¥1,111 million-20.5%
Net income¥822 million-19.4%
Selling, general and administrative expenses¥1,406 million
Gross Profit Margin
Rate68
Year-on-year change (points)-3
Operating profit margin
Rate28.2
Year-on-year change (points)-8.9
Full-year earnings forecast
Net Sales
¥11,428 million
Gross profit
¥7,888 million
Selling, general and administrative expenses
¥3,474 million
Operating profit
¥4,414 million
Ordinary income
¥4,437 million
Net income for the current fiscal year
¥3,220 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales30.9
Gross profit30.5
Selling, general and administrative expenses40.5
Operating profit22.6
Ordinary income25
Net income for the current fiscal year25.5
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Revenue decreased by ¥443 million, gross profit decreased by ¥420 million, selling, general and administrative expenses increased by ¥59 million, operating income decreased by ¥479 million, ordinary income decreased by ¥286 million, and interim net income decreased by ¥198 million.
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
COVID-19 is expected to subside temporarily before resurging in winter. Influenza is expected to spread earlier and expand rapidly during the 2026/2027 season as well. Demand for tests for other infectious diseases is expected to remain at approximately the same level as in the previous year overall. Specific assumptions regarding foreign exchange rates, raw material prices and other factors: not disclosed.New initiatives
- Launched a carbapenemase detection reagent in May 2026
- Launched the research-use reagent “Smart Gene NHPH” in July 2026
- Launched the in vitro diagnostic “Smart Gene Bordetella pertussis Nucleic Acid Kit” in August 2026
- Plans to launch the “RSV/hMPV High-Sensitivity Reagent” and “Smart Gene H. pylori S” during 2026
- Conceptualizing a successor to Smart Gene, next-generation infectious disease POCT, and the integration of testing data and use of AI
Key KPIsA metric the company considers important as a management benchmark.
- Cumulative Smart Gene units sold6,000 Units
- COVID-19 genetic testing kit tests sold27,000 TestingYear on year against the same period last year-66.3%
- COVID-19 antigen kit tests sold2,400,000 TestingYear on year against the same period last yearBroadly unchanged year on year
Segment results
Hospitals and Private Practitioners
Net Sales
¥3,372 million-11.2%
Hospitals and Private Practitioners (COVID-19 Test Reagents)
Net Sales
¥1,830 million-16.4%
Hospitals and Private Practitioners (Influenza-Only Test Reagents)
Net Sales
¥300 million+1.3%
Hospitals and Private Practitioners (Other Test Reagents and Equipment)
Net Sales
¥1,241 million-5.2%
OTC and Other
Net Sales
¥160 million-10.6%
Number of employees
Number of Employees196 people
Record date30 June 2026
Capital expenditures
¥116 million acquisitions of property, plant and equipment
Annual Dividend
Interim dividend of ¥50, year-end dividend of ¥50, annual dividend of ¥100 (forecast)Payout ratio
50| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | Second quarter (interim period) of the fiscal year ending December 2026 |
| Net Sales | ¥3,533 million (YoY -11.1%) |
| Operating profit | ¥996 million (YoY -32.5%) |
| Ordinary income | ¥1,111 million (YoY -20.5%) |
| Net income | ¥822 million (YoY -19.4%) |
| Gross Profit Margin | Rate 68 / Year-on-year change (points) -3 |
| Operating profit margin | Rate 28.2 / Year-on-year change (points) -8.9 |
| Selling, general and administrative expenses | ¥1,406 million |
| Full-year earnings forecast | Net Sales ¥11,428 million / Gross profit ¥7,888 million / Selling, general and administrative expenses ¥3,474 million / Operating profit ¥4,414 million / Ordinary income ¥4,437 million / Net income for the current fiscal year ¥3,220 million |
| Progress against full-year forecast | Net Sales 30.9 / Gross profit 30.5 / Selling, general and administrative expenses 40.5 / Operating profit 22.6 / Ordinary income 25 / Net income for the current fiscal year 25.5 |
| Segment results | Hospitals and Private Practitioners Net Sales ¥3,372 million (YoY -11.2%) / Hospitals and Private Practitioners (COVID-19 Test Reagents) Net Sales ¥1,830 million (YoY -16.4%) / Hospitals and Private Practitioners (Influenza-Only Test Reagents) Net Sales ¥300 million (YoY +1.3%) / Hospitals and Private Practitioners (Other Test Reagents and Equipment) Net Sales ¥1,241 million (YoY -5.2%) / OTC and Other Net Sales ¥160 million (YoY -10.6%) |
| Breakdown of Factors Affecting the Change | Revenue decreased by ¥443 million, gross profit decreased by ¥420 million, selling, general and administrative expenses increased by ¥59 million, operating income decreased by ¥479 million, ordinary income decreased by ¥286 million, and interim net income decreased by ¥198 million. |
| Key KPIs | Indicator name Cumulative Smart Gene units sold / Value 6,000 Units / Year on year against the same period last year Not disclosed, Indicator name COVID-19 genetic testing kit tests sold / Value 27,000 Testing / Year on year against the same period last year -66.25 Testing, Indicator name COVID-19 antigen kit tests sold / Value 2,400,000 Testing / Year on year against the same period last year Broadly unchanged year on year |
| Number of employees | Number of Employees 196 people / Record date 30 June 2026 |
| Assumptions Underlying the Business Outlook | COVID-19 is expected to subside temporarily before resurging in winter. Influenza is expected to spread earlier and expand rapidly during the 2026/2027 season as well. Demand for tests for other infectious diseases is expected to remain at approximately the same level as in the previous year overall. Specific assumptions regarding foreign exchange rates, raw material prices and other factors: not disclosed. |
| Annual Dividend | Interim dividend of ¥50, year-end dividend of ¥50, annual dividend of ¥100 (forecast) |
| Payout ratio | 50 |
| Capital expenditures | ¥116 million (acquisitions of property, plant and equipment) |
| New initiatives | Launched a carbapenemase detection reagent in May 2026, Launched the research-use reagent “Smart Gene NHPH” in July 2026, Launched the in vitro diagnostic “Smart Gene Bordetella pertussis Nucleic Acid Kit” in August 2026, Plans to launch the “RSV/hMPV High-Sensitivity Reagent” and “Smart Gene H. pylori S” during 2026, Conceptualizing a successor to Smart Gene, next-generation infectious disease POCT, and the integration of testing data and use of AI |
Items this document does not state (11)
Results for the three months of the current quarterSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales of genetic testing kits declined as the scale of COVID-19 infections diminished and the disease was reclassified to Category 5. Sales of antigen kits remained at approximately the same level as in the same period of the previous year, while sales of influenza-only test kits increased slightly. However, demand declined for tests for other infectious diseases and in the OTC segment. Gross profit also declined due to lower revenue and changes in the revenue mix, resulting in declines in each profit measure.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.